ViaCell (VIAC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ViaCell (VIAC)

VIAC 40.77

+3.6%

Dec 4 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Amy J	1/25/2005 10:11:08 PM
	Read Replies (1) of 9

"Earlier this month, we took a look at this company and its ultra-clever business model, which combines the promise of saving lives with the genius of charging storage fees for cord blood collected by its ViaCord subsidiary, in the style of such subscription-based companies as Tivo (Nasdaq: TIVO), Sirius (Nasdaq: SIRI), XM Satellite (Nasdaq: XMSR), and the like. Sadly, the genius of the model didn't translate into a well-considered coming-out party. It appears that the company and/or its underwriters, UBS (NYSE: UBS) and Credit Suisse Group (NYSE: CSR), gravely underestimated investor demand for this issue in pricing it at a measly $7 per share, a number that values the entire business at just over $260 million." fool.com A good problem to have.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next